NL192880C - Nucleïnezuur dat voor het oppervlakte-antigeen van een Hepatitis B virus codeert, peptide waarvoor het codeert, vector die het nucleïnezuur bevat , hybride-eiwit waarvoor het in de vector ingevoegde nucleïnezuur codeert, en vaccin dat het hybride-eiwit bevat. - Google Patents
Nucleïnezuur dat voor het oppervlakte-antigeen van een Hepatitis B virus codeert, peptide waarvoor het codeert, vector die het nucleïnezuur bevat , hybride-eiwit waarvoor het in de vector ingevoegde nucleïnezuur codeert, en vaccin dat het hybride-eiwit bevat. Download PDFInfo
- Publication number
- NL192880C NL192880C NL8020315A NL8020315A NL192880C NL 192880 C NL192880 C NL 192880C NL 8020315 A NL8020315 A NL 8020315A NL 8020315 A NL8020315 A NL 8020315A NL 192880 C NL192880 C NL 192880C
- Authority
- NL
- Netherlands
- Prior art keywords
- nucleic acid
- gene
- vector
- encoding
- peptide
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims description 50
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 47
- 239000013598 vector Substances 0.000 title claims description 28
- 102000004169 proteins and genes Human genes 0.000 title claims description 25
- 150000007523 nucleic acids Chemical class 0.000 title claims description 24
- 108020004707 nucleic acids Proteins 0.000 title claims description 23
- 102000039446 nucleic acids Human genes 0.000 title claims description 23
- 241000700721 Hepatitis B virus Species 0.000 title claims description 10
- 239000000427 antigen Substances 0.000 title claims description 9
- 102000036639 antigens Human genes 0.000 title claims description 9
- 108091007433 antigens Proteins 0.000 title claims description 9
- 229960005486 vaccine Drugs 0.000 title claims description 6
- 239000013612 plasmid Substances 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 230000035772 mutation Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 101150069452 z gene Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 47
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102000005936 beta-Galactosidase Human genes 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 241001515965 unidentified phage Species 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- 101000991414 Aspergillus oryzae (strain ATCC 42149 / RIB 40) Nuclease S1 Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 101150017816 40 gene Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZVIVKIWKSGLFQN-UHFFFAOYSA-N dimethyl sulfate;hydrazine Chemical compound NN.COS(=O)(=O)OC ZVIVKIWKSGLFQN-UHFFFAOYSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- -1 proline amino acid Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
- C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/22—Viral peptide or viral protein
- Y10S930/223—Hepatitis related
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7921811 | 1979-08-03 | ||
| FR7921811A FR2464269B1 (fr) | 1979-08-30 | 1979-08-30 | Sequence nucleotidique codant l'antigene de surface du virus de l'hepatite b, procede permettant son obtention et antigene obtenu |
| FR8009039 | 1980-04-22 | ||
| FR8009039A FR2480779B2 (fr) | 1979-08-30 | 1980-04-22 | Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur |
| FR8000133 | 1980-08-29 | ||
| PCT/FR1980/000133 WO1981000577A1 (fr) | 1979-08-30 | 1980-08-29 | Sequence nucleotidique codant l'antigene de surface du virus de l'hepatite b, vecteur contenant ladite sequence nucleotidique, procede permettant son obtention et antigene obtenu |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NL8020315A NL8020315A (nl) | 1981-07-01 |
| NL192880B NL192880B (nl) | 1997-12-01 |
| NL192880C true NL192880C (nl) | 1998-04-02 |
Family
ID=26221334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8020315A NL192880C (nl) | 1979-08-30 | 1980-08-29 | Nucleïnezuur dat voor het oppervlakte-antigeen van een Hepatitis B virus codeert, peptide waarvoor het codeert, vector die het nucleïnezuur bevat , hybride-eiwit waarvoor het in de vector ingevoegde nucleïnezuur codeert, en vaccin dat het hybride-eiwit bevat. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4428941A (de) |
| JP (1) | JPS6362198B2 (de) |
| BE (1) | BE884988A (de) |
| CA (1) | CA1163585A (de) |
| CH (1) | CH663796A5 (de) |
| DE (1) | DE3049831C2 (de) |
| FR (1) | FR2480779B2 (de) |
| GB (1) | GB2070621B (de) |
| LU (1) | LU88365I2 (de) |
| NL (1) | NL192880C (de) |
| SE (3) | SE8102726L (de) |
| WO (1) | WO1981000577A1 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6416996B1 (en) * | 1978-12-18 | 2002-07-09 | Institut Pasteur | Nucleotide sequence comprising the genome of hepatitis b virus, nucleotide sequence coding the surface antigen of the hepatitis b virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby |
| DK171727B1 (da) * | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| EP0182442B2 (de) * | 1978-12-22 | 1996-04-03 | Biogen, Inc. | Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben |
| US6270955B1 (en) | 1978-12-22 | 2001-08-07 | Biogen, Inc. | Pharmaceutical compositions and methods for producing antibodies to hepatitis b virus and kits and methods for detecting antibodies to hepatitis b virus |
| US5196194A (en) * | 1979-05-24 | 1993-03-23 | The Regents Of The University Of California | Vaccines containing Hepatitis B S-protein |
| IE52036B1 (en) * | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
| USRE34705E (en) * | 1979-08-30 | 1994-08-23 | Institut Pasteur | Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby |
| DE3176404D1 (en) * | 1980-04-22 | 1987-10-08 | Pasteur Institut | Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine |
| NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4769238A (en) | 1981-08-04 | 1988-09-06 | The Regents Of The University Of California | Synthesis of human virus antigens by yeast |
| ZW18282A1 (en) * | 1981-08-31 | 1983-03-23 | Genentech Inc | Preparation of polypeptides in vertebrate cell culture |
| US4741901A (en) * | 1981-12-03 | 1988-05-03 | Genentech, Inc. | Preparation of polypeptides in vertebrate cell culture |
| EP0082789B1 (de) * | 1981-12-22 | 1987-04-08 | Baylor College of Medicine | Immunologische Zusammensetzung und Methode für Hepatitis-B-Virus |
| US4593002A (en) * | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
| JPS5931799A (ja) * | 1982-08-16 | 1984-02-20 | Science & Tech Agency | Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド |
| US4820642A (en) * | 1983-04-04 | 1989-04-11 | The Regents Of The University Of California | Amplified expression vector |
| US4575495A (en) * | 1983-05-12 | 1986-03-11 | New York Blood Center, Inc. | Synthetic antigenic peptide derived from Hepatitis B surface antigen |
| US5204096A (en) * | 1984-03-07 | 1993-04-20 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| US4847080A (en) * | 1984-03-07 | 1989-07-11 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers |
| US5324513A (en) * | 1984-03-07 | 1994-06-28 | Institut Pasteur | Composition useful for the fabrication of vaccines |
| US4861588A (en) * | 1985-02-05 | 1989-08-29 | New York Blood Center, Inc. | Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers |
| US4599230A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| AU579148B2 (en) * | 1984-03-09 | 1988-11-17 | Scripps Clinic And Research Foundation | Synthetic hepatitis b virus vaccine including both t cell and b cell determinants |
| US4599231A (en) * | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| SU1470739A1 (ru) * | 1984-07-16 | 1989-04-07 | Всесоюзный кардиологический научный центр АМН СССР | Гексапептид, обладающий гепатопротективным действием |
| US4743553A (en) * | 1984-07-18 | 1988-05-10 | W. R. Grace & Co. | Synthetic genes for bovine parainfluenza virus |
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| JPH0745514B2 (ja) * | 1985-08-20 | 1995-05-17 | 武田薬品工業株式会社 | 新規蛋白質およびその製造法 |
| US4895800A (en) * | 1985-11-26 | 1990-01-23 | Phillips Petroleum Company | Yeast production of hepatitis B surface antigen |
| WO1987007896A1 (en) * | 1986-06-20 | 1987-12-30 | Scripps Clinic And Research Foundation | T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen |
| US4778784A (en) * | 1987-01-07 | 1988-10-18 | Baylor College Of Medicine | Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus |
| CA1341074C (en) * | 1987-06-22 | 2000-08-08 | Hans A. Thoma | Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine |
| US5162226A (en) | 1987-08-24 | 1992-11-10 | University Of Tennessee Research Corp. (U.T.R.C.) | Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products |
| US5359100A (en) * | 1987-10-15 | 1994-10-25 | Chiron Corporation | Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers |
| WO1990002762A1 (en) | 1988-09-02 | 1990-03-22 | The Rockefeller University | Macrophage-derived inflammatory mediator (mip-2) |
| CA2065287C (en) * | 1989-09-15 | 1999-12-21 | Tatsuo Miyamura | New hcv isolates |
| EP0491077A1 (de) * | 1990-12-19 | 1992-06-24 | Medeva Holdings B.V. | Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten |
| US6322789B1 (en) | 1991-08-26 | 2001-11-27 | Epimmune, Inc. | HLA-restricted hepatitis B virus CTL epitopes |
| US6607727B1 (en) * | 1991-08-26 | 2003-08-19 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus |
| US5612487A (en) * | 1991-08-26 | 1997-03-18 | Edible Vaccines, Inc. | Anti-viral vaccines expressed in plants |
| US20010053367A1 (en) * | 1991-08-26 | 2001-12-20 | Prodigene, Inc. | Vaccines expressed in plants |
| US5780036A (en) * | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| US6419931B1 (en) | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| US5484719A (en) | 1991-08-26 | 1996-01-16 | Edible Vaccines, Inc. | Vaccines produced and administered through edible plants |
| US6689363B1 (en) | 1992-01-29 | 2004-02-10 | Epimmune Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| US7611713B2 (en) * | 1993-03-05 | 2009-11-03 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide compositions |
| US20110097352A9 (en) * | 1992-01-29 | 2011-04-28 | Pharmexa Inc. | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions |
| US6235288B1 (en) | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| EP0752853B1 (de) | 1993-03-10 | 2005-09-21 | Smithkline Beecham Corporation | Phosphodiesterase des menschlichen gehirns |
| CA2232023A1 (en) * | 1995-09-15 | 1997-03-20 | John A. Howard | Expression cassettes and methods for delivery of animal vaccines |
| US6087128A (en) * | 1998-02-12 | 2000-07-11 | Ndsu Research Foundation | DNA encoding an avian E. coli iss |
| AU2002305138A1 (en) * | 2001-04-09 | 2002-10-21 | Mayo Foundation For Medical Education And Research | Methods and materials for cancer treatment |
| US8029803B2 (en) | 2002-06-20 | 2011-10-04 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US8025873B2 (en) * | 2002-06-20 | 2011-09-27 | Paladin Labs, Inc. | Chimeric antigens for eliciting an immune response |
| US20040057969A1 (en) * | 2002-09-20 | 2004-03-25 | Smith Mark L | Compositions containing stabilized hepatitis antigen and methods of their use |
| US8007805B2 (en) * | 2003-08-08 | 2011-08-30 | Paladin Labs, Inc. | Chimeric antigens for breaking host tolerance to foreign antigens |
| CN101300355A (zh) * | 2005-10-13 | 2008-11-05 | 威瑞克斯医药公司 | 包含丙型肝炎病毒多肽和用于引起免疫应答的Fc片段的嵌合抗原 |
| US8969033B2 (en) | 2005-11-02 | 2015-03-03 | Battelle Energy Alliance, Llc | Alteration and modulation of protein activity by varying post-translational modification |
| JP4685674B2 (ja) * | 2006-03-20 | 2011-05-18 | 株式会社東海理化電機製作所 | ウエビング巻取装置 |
| US8492114B2 (en) | 2008-01-25 | 2013-07-23 | Battelle Energy Alliance, Llc | Methods of combined bioprocessing and related microorganisms, thermophilic and/or acidophilic enzymes, and nucleic acids encoding said enzymes |
| US7923234B2 (en) | 2008-01-25 | 2011-04-12 | Battelle Energy Alliance, Llc | Thermal and acid tolerant beta-xylosidases, genes encoding, related organisms, and methods |
| US9732330B2 (en) | 2008-01-25 | 2017-08-15 | Battelle Energy Alliance, Llc | Methods of combined bioprocessing and related microorganisms, thermophilic and/or acidophilic enzymes, and nucleic acids encoding said enzymes |
| US8426185B2 (en) | 2008-01-31 | 2013-04-23 | Battelle Energy Alliance, Llc | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods |
| US8557557B2 (en) | 2008-01-31 | 2013-10-15 | Battelle Energy Alliance, Llc | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods |
| US8497110B2 (en) | 2008-01-31 | 2013-07-30 | Battelle Energy Alliance, Llc | Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods |
| AU2009210489A1 (en) | 2008-01-31 | 2009-08-13 | Battelle Energy Alliance, Llc | Thermophilic and thermoacidophilic biopolymer- degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods |
| WO2009137145A2 (en) | 2008-02-22 | 2009-11-12 | Battelle Energy Alliance, Llc | Transcriptional control in alicyclobacillus acidocaldarius and associated genes, proteins, and methods |
| CN102105588A (zh) | 2008-02-26 | 2011-06-22 | 巴特勒能源同盟有限公司 | 来自酸热脂环酸杆菌的嗜热的与嗜热嗜酸的糖转运蛋白的基因和酶以及相关生物、方法 |
| JP2011517931A (ja) | 2008-02-27 | 2011-06-23 | バテル エナジー アライアンス，エルエルシー | アリサイクロバチルス・アシドカルダリウスおよび関連生物体からの好熱性および好熱好酸性グリコシル化遺伝子および酵素、方法 |
| MX2010009243A (es) | 2008-02-28 | 2010-11-30 | Battelle Energy Alliance Llc | Genes de metabolismo termofilico y termoacidofilico y enzimas a partir de alicyclobacillus acidocaldarius, metodos y organismos relacionados. |
| WO2010096693A2 (en) | 2009-02-19 | 2010-08-26 | Mayo Foundation For Medical Education And Research | Methods and materials for generating t cells |
| US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
| US20110275135A1 (en) | 2010-05-05 | 2011-11-10 | Battelle Energy Alliance, Llc | Genetic elements, proteins, and associated methods including application of additional genetic information to gram (+) thermoacidophiles |
| CA2864841C (en) | 2012-02-17 | 2020-07-07 | Keith L. Knutson | Methods and materials for generating cd8+ t cells having the ability to recognize cancer cells expressing a her2/neu polypeptide |
| WO2013140393A1 (en) | 2012-03-21 | 2013-09-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peptides derived from the d1 - domain of nkp46 |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK173092B1 (da) * | 1977-11-08 | 2000-01-10 | Genentech Inc | Rekombinant plasmid, fremgangsmåde til fremstilling af plasmidet, bakterie indeholdende plasmidet, samt fremgangsmåde til f |
| FR2422685A1 (fr) * | 1978-04-14 | 1979-11-09 | Pasteur Institut | Vecteurs, derives du bacteriophage lambda, permettant l'insertion et l'expression d'un gene, procaryote ou eucaryote, sous le controle du promoteur et de l'operateur de l'operon lactose de la bacterie escherichia coli |
| FR2428075A1 (fr) * | 1978-06-08 | 1980-01-04 | Pasteur Institut | Procede de production de proteines par expression des genes correspondants dans des bacteries et vecteurs susceptibles d'etre mis en oeuvre dans de tels procedes |
| FR2444713A1 (fr) * | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| DK171727B1 (da) * | 1978-12-22 | 1997-04-14 | Biogen Inc | Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion |
| IE52036B1 (en) * | 1979-05-24 | 1987-05-27 | Univ California | Non-passageable viruses |
-
1980
- 1980-04-22 FR FR8009039A patent/FR2480779B2/fr not_active Expired
- 1980-08-29 JP JP55501975A patent/JPS6362198B2/ja not_active Expired
- 1980-08-29 BE BE0/201915A patent/BE884988A/fr not_active IP Right Cessation
- 1980-08-29 WO PCT/FR1980/000133 patent/WO1981000577A1/fr active Application Filing
- 1980-08-29 NL NL8020315A patent/NL192880C/nl not_active IP Right Cessation
- 1980-08-29 GB GB8113283A patent/GB2070621B/en not_active Expired
- 1980-08-29 CA CA000359303A patent/CA1163585A/fr not_active Expired
- 1980-08-29 US US06/261,199 patent/US4428941A/en not_active Ceased
- 1980-08-29 DE DE19803049831 patent/DE3049831C2/de not_active Expired - Lifetime
- 1980-08-29 CH CH2854/81A patent/CH663796A5/fr not_active IP Right Cessation
-
1981
- 1981-04-29 SE SE8102726D patent/SE8102726L/xx not_active Application Discontinuation
- 1981-04-29 SE SE8102726A patent/SE463459B/sv not_active IP Right Cessation
-
1983
- 1983-06-16 SE SE8303463A patent/SE462530B/sv not_active IP Right Cessation
-
1993
- 1993-07-02 LU LU88365C patent/LU88365I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE463459B (sv) | 1990-11-26 |
| NL8020315A (nl) | 1981-07-01 |
| WO1981000577A1 (fr) | 1981-03-05 |
| CH663796A5 (fr) | 1988-01-15 |
| DE3049831T1 (de) | 1982-06-16 |
| SE462530B (sv) | 1990-07-09 |
| FR2480779B2 (fr) | 1986-07-18 |
| SE8102726L (sv) | 1981-04-29 |
| FR2480779A2 (fr) | 1981-10-23 |
| SE8303463L (sv) | 1983-06-16 |
| BE884988A (fr) | 1981-03-02 |
| GB2070621B (en) | 1983-05-18 |
| NL192880B (nl) | 1997-12-01 |
| JPS56501128A (de) | 1981-08-13 |
| SE8303463D0 (sv) | 1983-06-16 |
| JPS6362198B2 (de) | 1988-12-01 |
| LU88365I2 (fr) | 1994-05-04 |
| DE3049831C2 (de) | 1992-08-27 |
| CA1163585A (fr) | 1984-03-13 |
| SE460727B (sv) | 1989-11-13 |
| GB2070621A (en) | 1981-09-09 |
| US4428941A (en) | 1984-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL192880C (nl) | Nucleïnezuur dat voor het oppervlakte-antigeen van een Hepatitis B virus codeert, peptide waarvoor het codeert, vector die het nucleïnezuur bevat , hybride-eiwit waarvoor het in de vector ingevoegde nucleïnezuur codeert, en vaccin dat het hybride-eiwit bevat. | |
| EP0013828B2 (de) | Rekombinante DNA, damit transformierte Wirtsorganismen und Verfahren zur Herstellung von Polypeptiden | |
| US5314808A (en) | Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of a B viral hepatitis, and preparations containing the expression products of said DNAs | |
| Will et al. | Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. | |
| EP0244924B1 (de) | Herstellung von Vakkzinen gegen Hepatitis B-Virus | |
| Nassal | Total chemical synthesis of a gene for hepatitis B virus core protein and its functional characterization | |
| JPS6321476B2 (de) | ||
| JPS6155950B2 (de) | ||
| HU196625B (en) | Process for producing hepatitis b virus vaccine | |
| US4963483A (en) | Method for producing hepatitis B virus proteins in yeast | |
| EP0182442B2 (de) | Rekombinante DNS-Moleküle und Verfahren zur Herstellung derselben | |
| EP0528903B1 (de) | Methoden zur verhinderung von viralen replikationen | |
| JPS62155092A (ja) | シヤトルベクタ− | |
| JPH0543352B2 (de) | ||
| USRE34705E (en) | Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby | |
| US6096879A (en) | Nucleotide sequence comprising the genome of hepatitis B virus, nucleotide sequence coding the surface antigen of the hepatitis B virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby | |
| US6416996B1 (en) | Nucleotide sequence comprising the genome of hepatitis b virus, nucleotide sequence coding the surface antigen of the hepatitis b virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby | |
| JPH084507B2 (ja) | 新規ｄｎａおよびポリペプチド | |
| JP2648122B2 (ja) | 新規ポリペプチドおよびその製造法 | |
| JPS6345227A (ja) | Ｂ型肝炎ウイルス表面抗原蛋白質 | |
| JP2704258B2 (ja) | 組み換えワクチニアウイルス | |
| JP2749010B2 (ja) | 新規ｄｎａおよびそれを用いたポリペプチドの製造法 | |
| CA1203763A (fr) | Proteine hybride codee par un fragment d'adn | |
| JP3305342B2 (ja) | Ｂ型肝炎ウイルスタンパク質の製造方法 | |
| CH666278A5 (fr) | Peptide immunogene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BA | A request for search or an international-type search has been filed | ||
| BB | A search report has been drawn up | ||
| BC | A request for examination has been filed | ||
| V4 | Discontinued because of reaching the maximum lifetime of a patent |
Free format text: 20000829 |